Revenue Performance - Q3 2024 revenues reached $864.4 million, a 16.4% increase year-over-year, with organic revenue growth of 3.1% and constant-exchange rate (CER) revenue growth of 15.7%[1][2] - Updated FY2024 revenue guidance is set at $3.34 to $3.37 billion, indicating a year-over-year growth of 12.5% to 13.5%, with organic revenue growth projected at 3% to 4%[5][6] - For the first nine months of 2024, revenues totaled $2.39 billion, a 13.1% increase from $2.11 billion in the same period of 2023, with organic growth of 4.0%[4] - Total revenue for the three months ended September 30, 2024, was $864.4 million, an increase of 16.3% compared to $742.8 million for the same period in 2023[16] - Revenue for the three months ended September 30, 2024, was $864.4 million, representing a growth rate of 16.4% compared to $742.8 million in the same period of 2023[18] - Revenue from Bruker BioSpin segment for the three months ended September 30, 2024, was $233.0 million, up from $198.3 million in 2023, representing a growth of 17.4%[29] - Revenue from Bruker CALID segment for the nine months ended September 30, 2024, reached $772.9 million, compared to $703.2 million in 2023, indicating a growth of 9.9%[29] - Total revenue from the United States for the three months ended September 30, 2024, was $239.0 million, an increase from $211.1 million in 2023, marking a growth of 13.2%[30] - Total revenue from the Asia Pacific region for the nine months ended September 30, 2024, was $711.7 million, compared to $692.8 million in 2023, reflecting a growth of 2.1%[30] Profitability Metrics - GAAP diluted EPS for Q3 2024 was $0.27, down from $0.60 in Q3 2023; non-GAAP diluted EPS was $0.60, an 18.9% decrease from $0.74 in Q3 2023[3] - Non-GAAP operating income for Q3 2024 was $129.1 million, a decrease of 12.9% compared to $148.3 million in Q3 2023, resulting in a non-GAAP operating margin of 14.9%[3] - Operating income decreased to $68.1 million for the three months ended September 30, 2024, down from $124.5 million in the same period last year[16] - Net income attributable to Bruker Corporation for the three months ended September 30, 2024, was $40.9 million, a decline of 53.6% from $88.1 million in the prior year[16] - Consolidated net income for the three months ended September 30, 2024, was $40.3 million, a decrease from $88.7 million in the same period of 2023[17] - Non-GAAP net income attributable to Bruker Corporation for the three months ended September 30, 2024, was $91.0 million, compared to $108.3 million in the same period of 2023[19] - GAAP gross profit for Q3 2024 was $418.8 million, with a gross profit margin of 48.4%, compared to $382.8 million and 51.5% in Q3 2023[21] - Non-GAAP gross profit for Q3 2024 was $442.2 million, representing a margin of 51.2%, while in Q3 2023 it was $391.6 million with a margin of 52.6%[21] - GAAP operating income for Q3 2024 decreased to $68.1 million (7.9% margin) from $124.5 million (16.8% margin) in Q3 2023[23] - Non-GAAP operating income for Q3 2024 was $129.1 million (14.9% margin), down from $148.3 million (20.0% margin) in Q3 2023[23] Cash Flow and Expenses - Net cash provided by operating activities for the three months ended September 30, 2024, was $38.4 million, compared to $44.1 million in the same period of 2023[18] - Cash flows from investing activities for the three months ended September 30, 2024, resulted in a net cash outflow of $67.6 million, compared to $155.0 million in the same period of 2023[17] - SG&A expenses for the three months ended September 30, 2024, were $229.9 million, an increase from $177.6 million in the same period of 2023[18] - Research and development expenses for the three months ended September 30, 2024, were $98.1 million, up from $71.3 million in the same period last year, reflecting a 37.6% increase[16] - Non-GAAP free cash flow for the three months ended September 30, 2024, was $5.8 million, a decrease from $17.2 million in the same period of 2023[19] Balance Sheet Highlights - Total current assets increased to $2,191.4 million as of September 30, 2024, compared to $2,164.2 million at the end of December 31, 2023[14] - Total assets rose significantly to $6,112.9 million as of September 30, 2024, compared to $4,249.9 million at the end of December 31, 2023[15] - Total shareholders' equity increased to $1,825.1 million as of September 30, 2024, up from $1,394.6 million at the end of December 31, 2023[15] - Long-term debt increased to $2,264.5 million as of September 30, 2024, compared to $1,160.3 million at the end of December 31, 2023[15] Market and Strategic Insights - The company anticipates a contribution from M&A of approximately 9.5% to FY2024 revenue growth[5] - Despite delays in biopharma and China recoveries, BSI organic bookings grew in the upper mid-single digits year-over-year in Q3[1] - The company is focused on integrating and improving strategic acquisitions to drive above-market organic revenue growth and margin expansion in 2025[1] - Foreign currency translation is expected to have a neutral impact on FY2024 revenue growth[5] - The effect of changes in foreign currency translation rates for the nine months ended September 30, 2024, was a positive $3.2 million, compared to a positive $3.4 million in 2023[28]

Biognosys' proprietary P2 Plasma Enrichment System enables plasma proteome profiling with unprecedented depth and throughput, both as contract research and in-house via licensing By offering the combination of NULISA™ affinity-based assays and TrueDiscovery® mass spectrometry-based plasma profiling with P2 Plasma Enrichment, Biognosys offers the industry's most comprehensive solutions for plasma proteomics Spectronaut® workflows for high-performance computing environments, post-translational modifications, ...

Bruker Corporation (BRKR) recently announced the release of its latest innovative neuroscience research solution, the OptoVolt module, at the Neuroscience 2024 conference. The module uniquely addresses the challenges of voltage imaging by providing scanner technology. The latest release expands Bruker's Ultima multiphoton microscope platform with advanced neuroscience research capabilities. BRKR's Likely Stock Trend Following the News Subsequent to the news, the share price of BRKR moved south 1.6% to $65.9 ...

Bruker Corporation's (BRKR) growth is backed by strong sales within its X-Ray and Nano Analytics businesses. Within the PCI division, expanding customer demand for pre-clinical MRI systems is highly encouraging. Meanwhile, the impact of macroeconomic pressure and currency fluctuation is likely to hurt the company's operational results. In the past year, this Zacks Rank #3 (Hold) company's shares have gained 10.4% compared with the industry's 27.5% growth and the S&P 500 composite's 34.9% gain. This renowned ...

Dublin, Sept. 20, 2024 (GLOBE NEWSWIRE) -- The "Dermatology Diagnostic Devices Market (2024 Edition): Analysis by Type (Imaging Devices, Microscopes, Immunoassays, Molecular Diagnostics, Others), Application, End-user and Region: Insights and Forecast (2020-2030)" report has been added to ResearchAndMarkets.com's offering. This report provides a complete analysis of the Global Dermatology Diagnostic Devices industry for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 202 ...

It has been about a month since the last earnings report for Bruker (BRKR) . Shares have added about 6.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Bruker due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Bruker Q2 Earnings Meet Estimates, Revenues Rise Y/Y B ...

Bruker Corporation's (BRKR) BioSpin Group has been witnessing impressive growth in its end markets and the strategic buyout of Chemspeed is poised to expand its potential. Within BSI Nano, AI is driving significant growth in the semiconductor and metrology tools. The latest innovations and acquisitions in the CALID business uphold its robust growth prospects. Meanwhile, the impact of macroeconomic pressure and competitive challenges may hurt the company's operational results. In the past year, this Zacks Ra ...

Under a strategic partnership with Alamar Biosciences, Biognosys is a provider of choice of NULISA multiplex assay services for biopharma research The NULISAseq™ CNS Disease and Inflammation panels are now available for customers as a contract research service from Biognosys' high-end proteomics facility in Europe By offering the combination of NULISA affinity-based assays and TrueDiscovery® mass spectrometrybased plasma profiling with P2 Plasma Enrichment, Biognosys offers the industry's most comprehensive ...

Bruker Corporation (BRKR) recently announced the successful installation and acceptance of a 1.2 GHz Avance Nuclear Magnetic Resonance ("NMR") spectrometer at the Korea Basic Science Institute ("KBSI"). As the first 1.2 GHz NMR system in the Asia-Pacific region, the solution has set a new benchmark for molecular, cell biology and disease research by ultra-high field NMR. The latest development from the company arrives right before the 30 ICMRBS (International Conference on Magnetic Resonance in Biological S ...

Have you evaluated the performance of Bruker's (BRKR) international operations during the quarter that concluded in June 2024? Considering the extensive worldwide presence of this scientific equipment maker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth. In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health an ...